revertant cell line isolated from H-ras transformed rat fibroblasts (1, 6) . Besides, high expression of H-rev107 has been observed in fibroblasts that are resistant toward transformation by activated H-ras oncogenes (1) . While H-rev107 overexpression in H-Ras-expressing cell lines resulted in reduction of colony formation and attenuated tumor growth in nude mice implying its tumor-suppressing activity (7), Siegrist et al. demonstrated a downregulation of H-rev107 expression in testicular germ cell tumors (8) . Its anti-proliferative activity was also indicated by the fact that cells overexpressing H-rev107 could not be maintained in culture for an extended period of time (1, 6) . Similarly, the H-rev107-related proteins, A-C1 and TIG3, significantly inhibited cell proliferation of H-ras-transformed NIH3T3 and wildtype 293 cells, respectively (2, 3) . By examining expression of H-rev107 in a variety of human and rat tumors and tumor cell lines, Husmann et al. (5) came to the conclusion that H-rev107 expression is silenced at the level of transcription and translation rather than by deletions or mutations that are frequently used for silencing of tumor suppressor genes.
As a first step towards studying its transcriptional regulation in cancer cells, we cloned and examined the murine H-rev107 gene and its promoter and identified a GC-box at -83/-75 that binds Sp1/Sp3 in vivo and is essential for the transcription of H-rev107 (9) . In the present study, we sought to determine the molecular mechanism by which H-rev107 expression is silenced in certain tumor cell lines. Using the H-rev107-negative murine lymphoma cell line, WEHI 7.1, as model system, we demonstrate that transcriptional silencing of H-rev107 strongly correlates with the methylation status of the CpG-rich region of its 5'-end, and involvement and in vivo binding of the methyl-CpG binding proteins, MeCP2 and MBD2 in the repression of Hrev107 transcription. DMEM supplemented with 10% fetal bovine serum. Human SK-BR-3 adenocarcinoma cells were grown in Mac Coy's 5a medium supplemented with 10% fetal bovine serum. Murine 3T3-L1 fibroblasts were maintained in DMEM containing 10% calf serum. For 5-aza-dC (Sigma) treatment, cells were split to low density 24 h before treatment. Cells were then treated with 5-aza-dC (5 or 10 µM) or were mock-treated with the same volume of phosphate buffered saline for 72-96 h changing the medium every 24 h.
EXPERIMENTAL PROCEDURES

Cell culture and 5-aza-dC treatment of cells-
RNA isolation, Northern blot analysis and reverse transcription-PCR-Total RNA was
isolated from tissues excised by rapid dissection, frozen in liquid nitrogen and homogenized in TRIZOL (Invitrogen) using a power homogenizer (Polytron). Total RNA was isolated from cell lines using TRIZOL. Northern blot analysis was performed as described recently (10 Plasmid constructs-The construction of all H-rev107-luciferase reporter constructs used in this study has been described previously (9) . The cDNA of MeCP2 was released by an Eco RI digest from pCMV-MeCP2-HA, a generous gift from A. Bird (University of Edinburgh, UK), and cloned into pcDNA3.1(+) (Invitrogen) to construct pcDNA3.1-MeCP2-HA. Similarly, the cDNAs of MBD2a and MBD3 were released by Hind III/Xho I digests from pcDNA3-HAhMBD2a and pcDNA3-HA-hMBD3 (generous gifts from F. Ishikawa and M. Saito, Tokyo
Institute of Technology, Yokohama, Japan) and cloned into pcDNA3.1(+) to obtain pcDNA3.1-HA-hMBD2a and pcDNA3.1-HA-hMBD3. pAc5(+) is an expression vector for Drosophila containing the Ac5 promoter and the vector backbone including the multiple cloning site of pcDNA3.1(+) without the CMV promoter. Using the same restriction sites as for the cloning into pcDNA3.1(+), the cDNAs of MeCP2, MBD2a and MBD3 were cloned into pAc5(+) to obtain pAc5-HA-MeCP2, pAc5-HA-hMBD2a and pAc5-HA-hMBD3, respectively. Luciferase activities were analyzed and normalized to protein concentration.
Chromatin immunoprecipitation assay-The chromatin immunoprecipitation assay was exactly performed as described recently (9 University School of Medicine, Atlanta, GA) antiserum were added to the chromatin. Due to the high similarity between MBD2 and MBD3 (11), MBD2/3 antiserum is able to recognize both MBD2 and MBD3. Primers for analyzing samples by PCR are listed in Table 1 . CpG content (% observed / % expected) of more than 0.6 and an average (C+G) content of more than 50%. Nevertheless, to obtain precise information about the methylation status of the 5'-end of H-rev107, bisulfite genomic sequencing was carried out (Fig. 2B) . Genomic DNA is treated with bisulfite under conditions that convert unmethylated cytosine to uracil, whereas the 5-methylcytosine remains unchanged. Within the region analyzed, virtually all CpG sites were unmethylated in DNA from all mouse tissues studied suggesting that methylation of CpG dinucleotides does not play a role in tissue-specific differences in H-rev107 expression as detected by Northern blot analysis (Fig. 1A) . Similarly, the two H-rev107-positive nontransformed fibroblast cell lines, viz. NIH3T3 and 3T3-L1, showed no or only moderate methylation (mainly at +157 and +159) in the H-rev107 region studied. On the other hand, unlike in fibroblasts, the H-rev107-negative WEHI 7.1 cells showed almost complete methylation of the region between -171 and +251 of the H-rev107 gene. These results indicate that aberrant cytosine methylation of the 5'-H-rev107 gene is associated with transcriptional repression in WEHI 7.1.
RESULTS
Expression of H-rev107 in various murine tissues and cell lines-
Induction of H-rev107 expression by 5-aza-dC in WEHI 7.1 cells-To test the potential
role of DNA methylation in the control of H-rev107 expression, demethylation was induced by treatment with the demethylating agent, 5-aza-2'-deoxycytidine. WEHI 7.1 cells were grown for 24 h to 72 h in the presence of 1 to 5 µM 5-aza-dC. Indeed, 5-aza-dC treatment allowed reexpression of H-rev107 as shown by RT-PCR (Fig. 3A) . Moreover, the expression of H-rev107
in 5-aza-dC-treated cells progressively decreased after withdrawal of the demethylating agent and disappeared almost entirely after about 3 weeks of culture (Fig. 3B ). The gradual disappearance of H-rev107 expression in the cell population subsequent to 5-aza-dC treatment might have resulted either from a gradual remethylation of the demethylated cells or from selection against the most demethylated, growth impaired cells. The latter scenario has been described to be the cause for the progressive disappearance of MAGE-A1 re-expression in melanoma cells after withdrawal of 5-aza-dC (14) . However, bisulfite genomic sequencing indicated that the 5'-end of proteins also showed an inhibitory effect on mock-methylated promoter at a lower but significant level of 30 -40%. Inhibitory effects of MeCP2 on unmethylated promoter constructs have been described recently for the placental lactogen I, BRCA1 and cyclin A1 genes (18, 19, 20) . This phenomenon probably was caused by a non-specific binding activity of MeCP2 as observed by (Fig. 6A) .
Nan et al. (21).
MeCP2/MBD2-binding to the 5'-end of H-rev107 in vivo-
In WEHI 7.1 cells, not only H-rev107 is silenced but also the cyclin-dependent kinase inhibitor p15 Ink4b (Fig. 6B) MeCP2/MBD2 binding to the 5'-region to nondetectable levels (Fig. 6C) . As a control, we examined MeCP2/MBD2 binding to the abundantly expressed gene fatty acid synthase (FAS; exon 32). As expected, we did not detect any MeCP2/MBD2 antibody-specific binding to this gene in either untreated or azacytidine treated cells (Fig. 6D) .
DISCUSSION
Since H-rev107 expression has been previously shown to be consistently dowregulated in miscellaneous tumorigenic cell lines derived from melanoma, neuroblastoma, adenocarcinoma and fibrosarcoma and being absent in several primary tumors (1, 5, 6, 8) , we undertook the present study to determine the molecular mechanism by which the H-rev107 gene is silenced in certain tumor cells. We and others (5, 8) speculated that the inactivation is due to a block of transcription rather than by mutation and deletion. Here, we provide evidence that H-rev107 
